Published in J Neurosci on February 13, 2008
Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol (2009) 3.04
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature (2012) 1.77
Aberrant protein s-nitrosylation in neurodegenerative diseases. Neuron (2013) 1.55
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem (2009) 1.49
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. J Med Chem (2010) 1.31
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J Neurochem (2009) 1.17
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease. Neuroscience (2009) 1.15
Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion (2012) 1.11
Enhanced capillary amyloid angiopathy-associated pathology in Tg-SwDI mice with deleted nitric oxide synthase 2. Stroke (2010) 1.05
Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets (2013) 1.05
Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation. J Cereb Blood Flow Metab (2013) 1.04
Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis (2011) 1.04
Microglia in Alzheimer's Disease: It's All About Context. Int J Alzheimers Dis (2012) 1.02
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro (2011) 1.01
The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis (2008) 0.99
Modulation of inflammation in transgenic models of Alzheimer's disease. J Neuroinflammation (2014) 0.99
Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. J Neurosci (2015) 0.96
Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis (2008) 0.95
Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PLoS One (2012) 0.93
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Amyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLoS One (2010) 0.91
Nitric oxide-mediated regulation of β-amyloid clearance via alterations of MMP-9/TIMP-1. J Neurochem (2012) 0.89
Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. Biochem Pharmacol (2014) 0.89
N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. J Biol Chem (2010) 0.88
Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxid Med Cell Longev (2013) 0.87
Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J Neuroimmune Pharmacol (2012) 0.86
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun (2015) 0.85
Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation. J Biol Chem (2011) 0.85
Neuropeptide Y: A stressful review. Neuropeptides (2015) 0.83
APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics. Neurodegener Dis (2012) 0.83
Global analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for synaptic pathology. Mol Cell Proteomics (2014) 0.83
Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis (2015) 0.82
Nitric oxide and geriatrics: Implications in diagnostics and treatment of the elderly. J Geriatr Cardiol (2011) 0.82
β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res Ther (2014) 0.82
Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase. J Neuroinflammation (2013) 0.81
Thalamic pathology and memory loss in early Alzheimer's disease: moving the focus from the medial temporal lobe to Papez circuit. Brain (2016) 0.80
Nitric oxide signaling is recruited as a compensatory mechanism for sustaining synaptic plasticity in Alzheimer's disease mice. J Neurosci (2015) 0.80
Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase. J Proteome Res (2013) 0.80
Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. Neurobiol Aging (2015) 0.80
Genetic animal models of cerebral vasculopathies. Prog Mol Biol Transl Sci (2012) 0.79
Alzheimer's in 3D culture: challenges and perspectives. Bioessays (2015) 0.79
Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol (2010) 0.79
mNos2 deletion and human NOS2 replacement in Alzheimer disease models. J Neuropathol Exp Neurol (2014) 0.78
Mutant amyloid precursor protein differentially alters adipose biology under obesogenic and non-obesogenic conditions. PLoS One (2012) 0.77
The impact of human and mouse differences in NOS2 gene expression on the brain's redox and immune environment. Mol Neurodegener (2014) 0.76
Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. J Neurosci (2016) 0.75
The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease. Neuroimage (2016) 0.75
Absence of Nitric Oxide Synthase 3 Increases Amyloid β-Protein Pathology in Tg-5xFAD Mice. Neurosci Med (2013) 0.75
mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement (2016) 0.75
Interleukin33 deficiency causes tau abnormality and neurodegeneration with Alzheimer-like symptoms in aged mice. Transl Psychiatry (2017) 0.75
Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. J Med Chem (2017) 0.75
TDP-43 expression influences amyloidβ plaque deposition and tau aggregation. Neurobiol Dis (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec (1991) 11.44
Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature (1995) 9.39
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol (1979) 6.07
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med (1998) 5.78
Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A (1995) 3.53
Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl (1998) 2.83
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res (2005) 2.67
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Neuron loss in APP transgenic mice. Nature (1998) 2.38
Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci (2004) 2.38
Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc (2006) 2.12
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Tau, tangles, and Alzheimer's disease. Biochim Biophys Acta (2005) 1.82
Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol (2003) 1.73
Mechanisms of the antioxidant effects of nitric oxide. Antioxid Redox Signal (2001) 1.70
Nitric oxide in neurodegeneration. Prog Brain Res (1998) 1.69
Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol (2005) 1.61
Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res (2001) 1.36
Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. Ann Neurol (1988) 1.33
Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol (1992) 1.33
Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav Genet (2006) 1.33
NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.27
The intimate relation between nitric oxide and superoxide in apoptosis and cell survival. Antioxid Redox Signal (2005) 1.27
Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int (2006) 1.24
Enhanced oxidative stress in iNOS-deficient mice after traumatic brain injury: support for a neuroprotective role of iNOS. J Cereb Blood Flow Metab (2005) 1.23
Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice. J Clin Invest (1999) 1.21
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol (2004) 1.18
Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp Gerontol (1999) 1.12
Tau gene mutations and their effects. Mov Disord (2005) 1.06
Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience (2007) 1.01
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem (2002) 1.00
Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. Int Immunopharmacol (2001) 1.00
Neuropeptide Y innervation of the hippocampal region in the rat and monkey brain. J Comp Neurol (1986) 0.98
Species differences in the generation of reactive oxygen species by microglia. Mol Chem Neuropathol (1997) 0.97
Pathological consequences of inducible nitric oxide synthase expression in hippocampal slice cultures. Neuroscience (2005) 0.96
Implications of inducible nitric oxide synthase expression and enzyme activity. Antioxid Redox Signal (2000) 0.96
Natural cellular inhibitors of caspases. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.94
Comparison of pathological diagnostic criteria for Alzheimer disease. Alzheimer Dis Assoc Disord (1998) 0.90
Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis (2003) 0.90
Characterization of NO and cytokine production in immune-activated microglia and peritoneal macrophages derived from a mouse model expressing the human NOS2 gene on a mouse NOS2 knockout background. Antioxid Redox Signal (2006) 0.87
Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein--initial observations. Neuroscience (2000) 0.87
Modulation of memory processing by neuropeptide Y. Brain Res (1987) 0.87
Neurotoxicity of nitroxyl: insights into HNO and NO biochemical imbalance. Free Radic Biol Med (2005) 0.86
Nerve fibers containing neuropeptide Y in the cerebrovascular bed: immunocytochemistry, radioimmunoassay, and vasomotor effects. J Cereb Blood Flow Metab (1987) 0.85
Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol Neurobiol (1995) 0.84
Nitric oxide donors induce neurotrophin-like survival signaling and protect neurons against apoptosis. Mol Pharmacol (2005) 0.84
Increased HO-1 expression and decreased iNOS expression in the hippocampus from adult spontaneously hypertensive rats. Cell Biochem Biophys (2006) 0.84
Effects of neuropeptide Y and calcitonin gene-related peptide on local cerebral blood flow in rat striatum. J Cereb Blood Flow Metab (1989) 0.83
Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. Acta Neuropathol (2006) 0.83
Nerve growth factor-independent neuronal survival: a role for NO donors. Mol Pharmacol (2005) 0.81
Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol Psychiatry (1997) 0.80
Transient cerebral vasodilatory effect of neuropeptide Y mediated by nitric oxide. Brain Res Bull (1993) 0.79
Inducible nitric oxide synthase and cyclooxgenase-2 mediate protection of hydrogen peroxide preconditioning against apoptosis induced by oxidative stress in PC12 cells. Life Sci (2006) 0.78
Essential genes of a minimal bacterium. Proc Natl Acad Sci U S A (2006) 6.31
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
The flipped classroom: a course redesign to foster learning and engagement in a health professions school. Acad Med (2014) 4.75
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol (2010) 3.75
Intraoperative tissue identification using rapid evaporative ionization mass spectrometry. Sci Transl Med (2013) 3.26
Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A (2002) 3.04
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Solution NMR studies of the A beta(1-40) and A beta(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc (2004) 2.79
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation (2006) 2.23
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol (2011) 1.97
APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem (2003) 1.80
APOE genotype-specific differences in the innate immune response. Neurobiol Aging (2007) 1.75
Pharmacy student engagement, performance, and perception in a flipped satellite classroom. Am J Pharm Educ (2013) 1.65
Human T-cell leukemia virus type 1 (HTLV-1) bZIP protein interacts with the cellular transcription factor CREB to inhibit HTLV-1 transcription. J Virol (2006) 1.63
Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am J Pathol (2005) 1.61
Protein nitration is mediated by heme and free metals through Fenton-type chemistry: an alternative to the NO/O2- reaction. Proc Natl Acad Sci U S A (2002) 1.53
Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci (2007) 1.50
Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther (2011) 1.43
Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci (2011) 1.43
Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol (2011) 1.38
A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. Exp Neurol (2005) 1.34
Tau--an inhibitor of deacetylase HDAC6 function. J Neurochem (2009) 1.27
Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci (2009) 1.27
Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A (2007) 1.26
Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity. J Biol Chem (2012) 1.26
Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol (2006) 1.21
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J Neurotrauma (2007) 1.20
APOE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress. Neurobiol Aging (2002) 1.20
Guide for the use of nitric oxide (NO) donors as probes of the chemistry of NO and related redox species in biological systems. Methods Enzymol (2002) 1.20
Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta. Proc Natl Acad Sci U S A (2011) 1.19
SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood (2011) 1.18
Orthogonal properties of the redox siblings nitroxyl and nitric oxide in the cardiovascular system: a novel redox paradigm. Am J Physiol Heart Circ Physiol (2003) 1.15
Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J Pharmacol Exp Ther (2006) 1.14
The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J Biol Chem (2010) 1.14
Plant neighbor identity influences plant biochemistry and physiology related to defense. BMC Plant Biol (2010) 1.14
Precision high-throughput proton NMR spectroscopy of human urine, serum, and plasma for large-scale metabolic phenotyping. Anal Chem (2014) 1.12
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res (2014) 1.12
A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care (2006) 1.09
The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappaB activation. J Biol Chem (2008) 1.08
Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci (2005) 1.07
The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury. J Neurotrauma (2007) 1.07
Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. Stroke (2008) 1.07
Apolipoprotein E isoform mediated regulation of nitric oxide release. Free Radic Biol Med (2002) 1.06
Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits. Neurobiol Dis (2009) 1.06
Apolipoprotein E-mimetics inhibit neurodegeneration and restore cognitive functions in a transgenic Drosophila model of Alzheimer's disease. PLoS One (2009) 1.06
Enhanced capillary amyloid angiopathy-associated pathology in Tg-SwDI mice with deleted nitric oxide synthase 2. Stroke (2010) 1.05
Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. Pharmacogenomics (2007) 1.05
Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic. J Neurotrauma (2010) 1.05
Humanin rescues human cerebrovascular smooth muscle cells from Abeta-induced toxicity. J Neurochem (2003) 1.05
A chemical perspective on the interplay between NO, reactive oxygen species, and reactive nitrogen oxide species. Ann N Y Acad Sci (2002) 1.04
APOE genotype-specific differences in human and mouse macrophage nitric oxide production. J Neuroimmunol (2004) 1.04
Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. J Biol Chem (2003) 1.04
Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascade. FASEB J (2002) 1.03
Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci U S A (2005) 1.02
Sex steroids, APOE genotype and the innate immune system. Neurobiol Aging (2005) 1.02
Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in NO redox signaling and regulation. Antioxid Redox Signal (2003) 1.02
An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J Pharmacol Exp Ther (2010) 1.02
Apolipoprotein-E allele-specific regulation of nitric oxide production. Ann N Y Acad Sci (2002) 1.01
Diverse inflammatory responses in transgenic mouse models of Alzheimer's disease and the effect of immunotherapy on these responses. ASN Neuro (2011) 1.01
Degradation of amyloid beta protein by purified myelin basic protein. J Biol Chem (2009) 1.00
The tau N279K exon 10 splicing mutation recapitulates frontotemporal dementia and parkinsonism linked to chromosome 17 tauopathy in a mouse model. J Neurosci (2007) 1.00
Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci (2007) 1.00
Metabolomic and functional genomic analyses reveal varietal differences in bioactive compounds of cooked rice. PLoS One (2010) 1.00
Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem (2003) 0.99
The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J Alzheimers Dis (2008) 0.99
Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys (2002) 0.98
Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice. Neurobiol Aging (2005) 0.98
Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg Focus (2006) 0.98